title: Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
abstract: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with high morbidity. The Quality of Life (QoL) assessment in this patient group with a limited life expectancy and high recurrence rate is important. Published data show an impairment of postoperative Quality of Life at 3 months postoperatively with an improvement over 6-12 months at levels higher than the baseline. Standardized instruments QoL have to be included in clinical trials assessing the efficacy of CRS and HIPEC.
authors.affiliation: University Medical Center Regensburg, Regensburg, Germany. pompiliu.piso@klinik.uni-regensburg.de
authors.forename: Pompiliu
authors.initials: P
authors.lastname: Piso
authors.forename: Gabriel
authors.initials: G
authors.lastname: Glockzin
authors.forename: Phillipp
authors.initials: P
authors.lastname: von Breitenbuch
authors.forename: Felix Cristoph
authors.initials: FC
authors.lastname: Popp
authors.forename: Marc Hendrik
authors.initials: MH
authors.lastname: Dahlke
authors.forename: Hans J
authors.initials: HJ
authors.lastname: Schlitt
authors.forename: Aviram
authors.initials: A
authors.lastname: Nissan
mesh_terms: D010478:Chemotherapy, Cancer, Regional Perfusion; D003131:Combined Modality Therapy; D006801:Humans; D006979:Hyperthermia, Induced; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D011788:Quality of Life